

Investigation vignette

A 37 Year old Man with Intermittent Abdominal Pain and a Non-Lactic, Non-Ketone, High Anion Gap Metabolic Acidosis

CASE REPORT

A 37 year old man was admitted to the accident and emergency department complaining of intermittent abdominal pain and malaise for one month with nausea and vomiting for the past 3 days. His past medical history was unremarkable and his only medication was paracetamol.

On examination he was in sinus rhythm at a rate of 72 beats per minute, respiratory rate 28 per minute, temperature was 35.8°C and a blood pressure of 100/80 mmHg. On examination he had a soft abdomen with slight tenderness in the right upper quadrant with no guarding or rebound tenderness. No other abnormalities were found.

A central venous cannula was inserted into the right subclavian vein and an arterial cannula was inser-

ted into the right radial artery. The patient was resuscitated with 2 litres of 0.9% saline intravenously during the first 2 hours and one litre of 5% dextrose with 60 mmol of potassium chloride over the next 6 hours.

The plasma biochemistry on admission revealed a sodium of 137 mmol/L, potassium 3.4 mmol/L, bicarbonate 9 mmol/L and amylase of 110 U/L. The haemoglobin was 135 g/L and the white cell count was $8.2 \times 10^9/L$. The arterial blood gases revealed a PO_2 of 110 mmHg, PCO_2 12 mmHg and pH 7.24. The anion gap was 31.4 mEq/L, plasma lactate 1.1 mmol/L, acetoacetate 0.09 mmol/L and beta-hydroxy-ybutyrate 0.22 mmol/L. The plasma biochemical results during the first two days of treatment are shown in figure 1.

Name	Age	Sex
Mr. D. D.	37	M

	21/12	22/12	23/12		
Sodium	137	139	135	mmol/L	(135 - 145)
Potassium	3.4	3.4	3.6	mmol/L	(3.2 - 4.3)
Chloride	100	109	106	mmol/L	(99 - 109)
Bicarbonate	9	17	22	mmol/L	(22 - 32)
Anion gap	31.4	6.4	10.6	mEq/L	(8 - 16)
Creatinine	0.13	0.06	0.6	mmol/L	(0.05 - 0.12)
Glucose	7.8	6.5	5.7	mmol/L	(3.5 - 5.4)
LDH	213	168	132	U/L	(105 - 230)
ALT	238	124	90	U/L	(< 40)
AST	213	38	27	U/L	(< 45)
PO_2	110	88	87	mmHg	(80 - 105)
PCO_2	12	25	29	mmHg	(35 - 45)
pH	7.24	7.39	7.45		(7.35 - 7.45)
BE	-19	-8	-4	mmol/L	(-3 - + 3)
Lactate	1.1	0.9	1.2	mmol/L	(< 2.0)

Figure 1. Blood gases and plasma biochemical results on admission and during the next two days in the intensive care unit

Diagnosis: Pyroglutamic acidosis due to paracetamol toxicity.

As the patient admitted to taking up to 8 g of paracetamol daily for the three weeks prior to his admission, a serum paracetamol level was measured which recorded a level of 790 $\mu\text{mol/L}$. Subsequently, urinary electrophoresis and gas chromatography revealed a high pyroglutamic acid level.

Following his initial intravenous fluid resuscitation he was treated with intravenous N-acetyl cysteine (10 g over 15 min followed by 3 g in 4 h, followed by 10.5 g in 24 h for three days). Fluid therapy consisted of two litres of 4% dextrose and 0.18% saline with 60 mmol of potassium chloride daily for 48 hours. Sodium bicarbonate was not administered.

Unlike other reported cases of pyroglutamate acidosis,¹ the patient was not septic and did not have a severe systemic inflammatory response to his disorder. Twenty four after admission the serum paracetamol level was $< 5 \mu\text{mol/L}$.

Paracetamol toxicity usually causes a high anion gap metabolic acidosis due to a lactic acidosis.² However, a high anion gap metabolic acidosis with normal lactate and ketone levels has also been reported in paracetamol toxicity due to pyroglutamic acidosis.³⁻⁵ The diagnosis is made by detecting a high anion gap metabolic acidosis (not explained by an elevated plasma lactate, beta-hydroxybutyrate, acetoacetate, citrate, formate, salicylate, amino-acids or albumin) and detecting pyroglutamate (5-oxoproline) acidemia or aciduria. Pyroglutamate aciduria has also been described as a rare inherited metabolic disorder presenting in infancy, in children taking vigabatrin⁶ and in an adult patient with staphylococcal pneumonia taking flucloxacillin and netilmicin.⁷

Paracetamol toxicity (particularly in the presence of sepsis and glutathione depletion) causes a reversible inhibition of either glutathione synthetase or 5-oxoprolinase, increasing pyroglutamate levels due to an overproduction (secondary to inhibition of glutathione synthetase) or reduction in breakdown (due to inhibition of 5-oxoprolinase) of pyroglutamate.¹

The normal minimal threshold dose of paracetamol in an adult is 10 g before glutathione availability is exceeded,^{8,9} although in malnourished patients and following starvation, toxicity may occur after ingestion of 4 - 10 g of paracetamol.¹⁰

As well as the acidosis the patient also had biochemical evidence of hepatic injury with an elevated ALT, AST and LDH (although all were less than 1000 U/L). Renal insufficiency was also recorded on admission (e.g. creatinine 0.13 mmol/L) although this was probably a pre-renal effect as the blood pressure and

urine output increased and creatinine decreased rapidly with intravenous fluid therapy.

Standard therapy for paracetamol toxicity is intravenous N-acetylcysteine to enhance and replenish glutathione stores by acting as a precursor for glutathione synthesis,^{11,12} although N-acetylcysteine may also have direct antioxidant effects by acting as a glutathione substitute or even enhancing nontoxic sulphate conjugation of paracetamol.¹³

The acidosis, hepatic dysfunction and abdominal pain resolved over three days and the patient was discharged from the intensive care unit and has been symptom free for the last 2 months.

M. SANAP

Department of Critical Care Medicine, Flinders Medical Centre, Bedford Park, SOUTH AUSTRALIA

REFERENCES

1. Dempsey GA, Lyall HJ, Corke CF, Scheinkestel CD. Pyroglutamic acidemia: a cause of high anion gap metabolic acidosis. *Crit Care Med.* 2000;28:1803-1807.
2. Gray TA, Buckley BM, Vale JA. Hyperlactataemia and metabolic acidosis following paracetamol overdose. *Q J Med* 1987;65:811-121.
3. Creer MH, Lau BW, Jones JD, Chan KM. Pyroglutamic acidemia in an adult patient. *Clin Chem* 1989;35:684-686.
4. Pitt JJ, Hauser S. Transient 5-oxoprolineuria and high anion gap metabolic acidosis: clinical and biochemical findings in eleven subjects. *Clin Chem* 1998;44:1497-1503.
5. Pitt JJ, Brown GK, Clift V, Christodoulou J. Atypical pyroglutamic aciduria: possible role of paracetamol. *J Inher Metab Dis* 1990;13:755-756.
6. Bonham JR, Rattenbury JM, Meeks A, Pollitt RJ. Pyroglutamicaciduria from vigabatrin. *Lancet* 1989;i:1452-1453.
7. Croal BL, Glen AC, Kelly CJ, Logan RW. Transient 5-oxoprolineuria (pyroglutamic aciduria) with systemic acidosis in an adult receiving antibiotic therapy. *Clin Chem* 1998;44:336-340.
8. Prescott LF. Hepatotoxic dose of paracetamol. *Lancet* 1977;ii:142.
9. Mitchell JR, Thorgeirsson SS, Potter WZ, Jollow DJ, Kieser H. Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. *Clin Pharmacol Ther* 1974;16:676-684.
10. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol abuse. *JAMA* 1994;272:1845-1850.
11. Beatty P, Reed BJ. Influence of cysteine upon the glutathione status of isolated rat hepatocytes. *Biochem Pharmacol* 1981;30:1227-1230.

12. Meredith TJ, Prescott LF, Vale JA. Why do patients still die from paracetamol poisoning? *Br Med J* 1986;293:345-346.
13. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of

acetaminophen overdose. Analysis of the National Multicenter Study. *N Engl J Med* 1988;319:1557-1562.